Brentuximab for Relapsed Peripheral T-Cell Lymphoma

A total of 41% of patients responded, including those with low or undetectable CD30 target expression on the lymphoma cells.

Effective treatment for relapsed peripheral T-cell lymphoma (PTCL) remains an unmet clinical challenge, as patients treated with cytotoxic chemotherapy experience poor overall responses and short progression-free survival (PFS).

To assess the efficacy of the anti-CD30 drug-antibody conjugate brentuximab vedotin (BV) in patients with relapsed PTCL, investigators conducted an industry-sponsored, phase II multicenter trial of BV. Central hematopathology review was included to confirm histopathologic subtype and the level of CD30 expression by the lymphoma cells. Of the 35 enrolled patients, 13 had angioimmunoblastic T-cell lymphoma (AITL), and 22 had PTCL not otherwise specified.

A total of 14 patients (41%) responded, including 8 (24%) who achi…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Brentuximab for Relapsed Peripheral T-Cell Lymphoma

Topics

Reviewing Author